Wall Street Wire: StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data
Nuvectis Pharma (NVCT) said it licensed worldwide rights outside China to NXP100 and NXP200 from Haisco Pharmaceutical Group for $40M upfront plus up to $1.42B in milestones. NVCT cites Phase 3 results for NXP100 in PNH versus eculizumab: 59.5% vs 8.3% transfusion-free normal hemoglobin. Two China NMPA applications are under review, with decisions expected late 2026 to early 2027.
How this was made
The 30-second read
Why it matters
The combination of a new asset acquisition, Phase 3 head-to-head efficacy versus eculizumab, and an explicit China decision window provides a tradable catalyst path for NVCT tied to regulatory timing and competitive positioning in PNH.
Market read
Investors are being given a concrete regulatory calendar and a strong efficacy datapoint that can drive re-rating for NVCT’s rare-disease pipeline, especially given market momentum for oral therapies.
What to watch
The article does not quantify safety/tolerability, durability of response, or manufacturing and reimbursement hurdles, which can materially affect approval odds and peak sales assumptions.
Background
Nuvectis is transitioning from a single mid-stage oncology story to a rare-disease platform via a June licensing deal for NXP100 (oral PNH) and NXP200 (oncology) from Haisco, with China rights tied to NMPA review.
Ticker impact
Nuvectis secured worldwide rights outside China to NXP100 and NXP200 from Haisco, with Phase 3 head-to-head Phase 3 data and China regulatory review underway.
Bullish bias into the next regulatory milestones; near-term volatility likely as traders price the China NMPA review timeline.
The article discloses a new licensing transaction, specifies Phase 3 endpoint results versus eculizumab, and provides a concrete expected window for China approval decisions, all of which can re-rate risk and valuation for NVCT.
Market effects
Reinforces investor appetite for oral complement-pathway therapies in PNH and may raise competitive expectations for oral Factor B inhibitors versus infused standards.
China regulatory review timing (NMPA) becomes a key regional catalyst for PNH oral therapy adoption and peer read-through.
If NXP100’s efficacy translates clinically, it supports broader global shift from lifelong infusion regimens toward at-home oral dosing in PNH.
Counterpoint
The headline efficacy may not fully de-risk commercialization; regulatory outcomes in China and payer adoption could lag despite strong Phase 3 transfusion-free response.
Key entities
- companyNuvectis Pharma
NASDAQ-listed company (NVCT) licensing NXP100 and NXP200 and advancing NXP100 toward China regulatory decisions.
- companyHaisco Pharmaceutical Group
Licensor providing worldwide rights outside China to NXP100 and NXP200 to Nuvectis.
- assetNXP100
Once-daily oral Factor B inhibitor candidate for PNH with Phase 3 transfusion-free normal hemoglobin response data versus eculizumab.
- assetNXP200
Oncology asset included in the licensing deal, with additional program readouts expected later.
- regulatorNMPA
China’s National Medical Products Administration reviewing two marketing authorization applications for NXP100.
